Aug 04, 2025 • Zacks Commentary
SOMEWHAT-BULLISH
Aurinia ( AUPH ) Upgraded to Buy: Here's What You Should Know
Aurinia (AUPH) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Aug 01, 2025 • Motley Fool
SOMEWHAT-BULLISH
Aurinia ( AUPH ) Q2 Revenue Jumps 22%
Aurinia Pharmaceuticals ( NASDAQ:AUPH ) , a biopharmaceutical company focused on therapies for autoimmune diseases, released its second-quarter 2025 earnings on July 31, 2025. The headline news: revenue ( GAAP ) came in at $70.0 million, which exceeded analyst expectations of $63.8 million by ...
Jul 31, 2025 • Zacks Commentary
NEUTRAL
Aurinia Pharmaceuticals ( AUPH ) Q2 Earnings Miss Estimates
Aurinia (AUPH) delivered earnings and revenue surprises of -5.88% and +10.41%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Jul 02, 2025 • Zacks Commentary
NEUTRAL
Implied Volatility Surging for Aurinia Pharmaceuticals Stock Options
Investors need to pay close attention to AUPH stock based on the movements in the options market lately.
Jun 27, 2025 • Zacks Commentary
SOMEWHAT-BULLISH
Aurinia ( AUPH ) Surges 7.5%: Is This an Indication of Further Gains?
Aurinia (AUPH) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
May 30, 2025 • Zacks Commentary
NEUTRAL
Is the Options Market Predicting a Spike in Aurinia Pharmaceuticals ( AUPH ) Stock?
Investors need to pay close attention to Aurinia Pharmaceuticals (AUPH) stock based on the movements in the options market lately.